I believe a strong case can be made for IPCI's valuation to increase based on a full Seroquel approval/commercialization. I have heard from many people that until they "show me the money" it won't be factored in. So I would if they do commercialize Seroquel they have "showed me the money" and valuation should be adjusted upward accordingly.
Rexista depends on strength of lawsuit. If it is a very strong lawsuit with valid claims then Rexista value is low
In the other hand, if lawsuit is weak case, Purdue would go out if its way to settle for a royalty or just try to acquire Rexista before commercializations
Their patents lawyer can assess outcome with high accuracy